Get access

Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP-macaque model of Parkinson's disease

Authors

  • Tom H. Johnston PhD,

    1. Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada
    Search for more papers by this author
  • Anne van der Meij,

    1. Academic Medical Centre, University of Amsterdam, The Netherlands
    Search for more papers by this author
  • Jonathan M. Brotchie PhD,

    1. Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada
    Search for more papers by this author
  • Susan H. Fox MRCP (UK), PhD

    Corresponding author
    1. Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada
    2. Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto, Canada
    • Movement Disorders Clinic, MCL7.421, Toronto Western Hospital, 399 Bathurst St, Toronto, Ontario, Canada M5T 2S8

    Search for more papers by this author

  • Potential conflict of interest: Nothing to report.

Abstract

Levodopa-induced motor complications, including dyskinesia and wearing off, are troublesome side effects of treatment and impair quality of life in Parkinson's disease (PD) patients. The use of nondopaminergic agents as adjuncts to levodopa are potential options for managing these problems. Here, we asses the ability of the clinically available, selective histamine H2 antagonist, famotidine (1, 3, and 30 mg/kg) to treat levodopa-induced dyskinesia and wearing off in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-macaque model of PD. Famotidine (3 mg/kg) increased peak activity, enhanced peak anti-parkinsonian action (1 and 3 mg/kg), and extended duration of action (3 mg/kg, by 38%) of a low dose of levodopa (compared to low dose levodopa alone). Enhancement of anti-parkinsonian actions of low dose levodopa by famotidine (3 mg/kg) was associated with only mild, nondisabling dystonia. Famotidine had no effect on the anti-parkinsonian actions of high dose levodopa (compared to high dose levodopa alone). However, famotidine (1, 3, and 30 mg/kg) had a significant effect on chorea, but not dystonia, induced by high dose levodopa (compared to high dose levodopa alone). Famotidine increased high dose levodopa–induced “good quality” on time, i.e., on time not associated with disabling dyskinesia, by up to 28% (compared to high dose levodopa alone). In conclusion, famotidine, a drug currently available for use in the clinic, can enhance the peak-dose anti-parkinsonian actions and extend total duration of action of a low dose of levodopa, without producing disabling dyskinesia. Furthermore, in combination with a higher dose of levodopa, famotidine can reduce peak-dose levodopa-induced chorea and improve the quality of on-time. © 2010 Movement Disorder Society

Get access to the full text of this article

Ancillary